HuCAL

Type: Product
Name: HuCAL
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

WAG Honours Collectors with Bringing Shadow to Light Exhibition

: Throughout its more than one-hundred year history, the Winnipeg Art Gallery has benefited enormously from countless generous and discriminating individuals, families, and foundations who have donated their prized objects and contributed to the Gallery's ... [Published Noodls - Aug 28 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Sex talk without all the shame

by Anneliese HucalFor those of you that don't know me, my name is Anneliese and I am a storyteller. I specifically like to tell stories about sexual- ity, which is both the lifeblood and the bane of my existence.People are rather funny about sex. While ... [Published Individual.com - Aug 26 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

DENTAC welcomes new commander

Col. David Kryszak relinquished command of the Fort Leonard Wood Dental Activity to Col. Alex Eke during a ceremony Friday in the John B. Mahaffey Museum Complex.Col. George Hucal, Western Regional Dental Command commander, officiated the event.“I am ... [Published Guidon - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 2 reports

MorphoSys to Host Conference Call on License Agreement with Emergent to Co-Develop and Commercialize Prostate Cancer Drug Candidate MOR209/ES414

World News: 06:34 GMT Wednesday 20th August 2014 . [ MorphoSys AG via Globe Newswire via SPi World News ]This storyMARTINSRIED / MUNICH, Germany, Aug. 20, 2014 (GLOBE NEWSWIRE)On 19 August 2014, MorphoSys and Emergent BioSolutions Inc. announced an agreement ... [Published SPi World News - Aug 20 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

MorphoSys reports net loss for Q2, reaffirms annual guidance

MorphoSys AG, a German biotechnology company, has reported that net loss for the second quarter ended June 30, 2014 was E526.746, or E0.02 loss per diluted share, compared to a net profit of E11.11 million, or E0.47 per diluted share, for the same quarter ... [Published Individual.com - Aug 12 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 1 reports

MorphoSys AG Reports Results for the First Six Months of 2014

(GLOBE NEWSWIRE) -- (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced its financial results for the six months ending 30 June 2014. Group revenues from continuing operations were EUR 30.5 million (H1 2013: EUR 48.2 million). Reasons ... [Published Pettinga Financial Advisors - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 2 reports

MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2014 Results - Earnings Call Transcript

MorphoSys AG ( OTCPK:MPSYF ) Q2 2014 Earnings Conference Call July 28, 2014 8:00 AM ETOperatorLadies and gentlemen, welcome to the MorphoSys Quarterly Call on the Financial Results of Q2 2014. Please note that for the duration of the presentation, all ... [Published Seeking Alpha - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

MorphoSys AG Reports Results for the First Six Months of 2014

(GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced its financial results for the six months ending 30 June 2014. Group revenues from continuing operations were EUR 30.5 million (H1 2013: EUR 48.2 million). ... [Published Virtual Strategy Magazine - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

MorphoSys H1 Profit Decreases; Re-confirms Guidance For 2014

MorphoSys AG (MPSYY.PK) reported earnings before interest and taxes (EBIT) from continued operations of 0.4 million euros for the six months ending 30 June 2014, compared to 17.3 million euros, a year ago. Profit from continuing operations decreased to ... [Published RTTNews.com - Jul 28 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

Monoclonal antibodies against ANGPTL3

Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are ... [Published PharmCast - Jun 17 2014]

Quotes

"Small and quickly executed preparatory sketches and studies-objects that play an indelible role in an artist`s creative process-earn equal attention to finished canvases, final proofs, and end products, for example, raising the WAG's capacity to facilitate important primary re" states Kear...
be, "How much control of the world around me do I need to have in order to be comfortable?"
...55 million, compared to E48.23 million for the same period ended June 30, 2013. Jens Holstein, CFO of MorphoSys AG, said: "We are pleased with the first half of 2014 and are on track to meet our goals for the full year. With the first-time disclosure of a royalty rate for our HuCAL antibody gantenerumab we are able to provide more visibility on the long-term revenue potential of our partnered compounds."
"The second quarter saw excellent progress with regard to partnering our latest Ylanthia antibody technology. With Merck Serono and the Temple University's Moulder Center for Drug Discovery two new alliances were initiated that have the potential to expand our pipeline of exciting new drug candidates" stated Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

More Content

All (15) | News (14) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
WAG Honours Collectors with Bringing Shadow to ... [Published Noodls - Aug 28 2014]
Sex talk without all the shame [Published Individual.com - Aug 26 2014]
DENTAC welcomes new commander [Published Guidon - Aug 21 2014]
MorphoSys to Host Conference Call on License Ag... [Published SPi World News - Aug 20 2014]
MorphoSys to Host Conference Call on License Ag... [Published BusinessWeek - Aug 20 2014]
REG-Ad hoc: MorphoSys and Emergent BioSolutions... [Published Reuters - Aug 19 2014]
MorphoSys reports net loss for Q2, reaffirms an... [Published Individual.com - Aug 12 2014]
MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2014... [Published Seeking Alpha - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published Virtual Strategy Magazine - Jul 28 2014]
MorphoSys H1 Profit Decreases; Re-confirms Guid... [Published RTTNews.com - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published GlobeNewswire: Advertising News - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published Pettinga Financial Advisors - Jul 28 2014]
MorphoSys Provides Update on the Company's Prop... [Published OSIX News - Jul 28 2014]
Monoclonal antibodies against ANGPTL3 [Published PharmCast - Jun 17 2014]
MorphoSys gets clinical milestone from Novartis... [Published PharmaBiz - Feb 18 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
MorphoSys AG Reports Results for the First Six ... [Published GlobeNewswire: Advertising News - Jul 28 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.